Crossmark

1327 Novel GCN2 modulator HC-7366 decreases pulmonary metastases and reduces myeloid-derived suppressor cells

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.1327

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Drees, Jeremy

Chan, Anissa SH

Li, Yunfang

Kangas, Takashi

Zhang, Weiyu

Fumagalli, Maria

Dewji, Iman

Bieging-Rolett, Kathryn

Fujisawa, Sho

Huang, Sharon

Harrison, Ben

LaCayo, Ashley

Qiu, Xiaohong

Collette, Nick

Wang, Gemily

Tameire, Feven

Wojnarowicz, Paulina

Graham, James

Dudgeon, Crissy

Lightcap, Eric

Surguladze, David

Bose, Nandita
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct05121948 at ClinicalTrials.gov

Documents that mention this clinical trial

1327 Novel GCN2 modulator HC-7366 decreases pulmonary metastases and reduces myeloid-derived suppressor cells
https://doi.org/10.1136/jitc-2022-sitc2022.1327